ICD-10 Coding for Wegovy® (semaglutide) for Obesity Management(E66.0, E66.01, E66.01B)
Comprehensive guide on ICD-10 coding for Wegovy, including documentation requirements and billing considerations for obesity management.
Complete code families applicable to Wegovy® (semaglutide) for Obesity Management
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| E66.01 | Morbid (severe) obesity due to excess calories | Use for patients with BMI ≥40 and documented comorbidities. |
|
| E66.3 | Overweight | Use for patients with BMI 27-29.9 and documented CVD. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutWegovy® (semaglutide) for Obesity Management
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Wegovy® (semaglutide) for Obesity Management.
Missing BMI documentation
Impact
Clinical: Inaccurate patient assessment., Regulatory: Non-compliance with coding standards., Financial: Potential claim denials.
Mitigation
Ensure BMI is recorded at each visit., Cross-check documentation before submission.
Using BMI code without primary obesity code
Impact
Reimbursement: Claims may be denied., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate representation of patient condition.
Mitigation
Always pair BMI codes with appropriate E66 codes.
BMI documentation
Impact
Inadequate BMI documentation can lead to audit findings.
Mitigation
Ensure BMI is documented at every visit.